The objective of this study is to assess the long-term efficacy of "AGE among on deep periodontal pockets by different doses of "AGE" for a period of 18 months.

This is a randomized, controlled, examiner-blind, 4-treatment parallel group study. The study will be conducted at the Hebrew University, Hadassah, Israel. A sufficient number of subjects will be screened to obtain approximately 300 generally healthy adult volunteers with moderate to deep periodontal pockets.

Subjects will be stratified and randomly assigned equally to either one from the 3 regimen groups with different doses of AGE or a control group (Placebo).

Subjects will be requested to use the products at home for the duration of the study according to the written and verbal usage instructions given to them during product distribution. At Baseline, Month 6, Month 12, and Month 18, subjects will receive oral soft tissue exams, and will have periodontal measurements made as described in below.

All groups will receive supra-gingival dental prophylaxes every 6 month consistent with local norms and standards. Products will be re-supplied approximately every six months following Baseline. During study conduct, subjects with evidence of progressive periodontal disease (≥3 mm increases in pocket depth, attachment loss or recession) will be exited from the study and treated following local norms.

Inclusion Criteria:

• give written informed consent and receive a copy of their consent;
• be between the ages of 30-60 years;
• be in good general health as determined by the Investigator/designee based on a review of the medical history/update for participation in the study;
• possess a minimum of 16 natural teeth (excluding third molars) with facial and lingual scorable surfaces;
• have at least 20 bleeding sites (sum of sites with a score of 1 or 2 on the GBI index);
• have at least: 3 eligible periodontal pockets sites (PPD 3.5-6 mm, bleeding);
• agree to delay any elective dentistry until study completion, including additional dental prophylaxes outside the study protocol;
• agree to refrain from using any non-study oral hygiene products for the study duration (subject will be allowed to continue using floss but they will be instructed not to add/change any other oral hygiene products, including whitening products etc);
• agree not to participate in any other oral care clinical study for the duration of this study;
• agree to return for their scheduled visits and follow study procedures;

Exclusion Criteria:

• • severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or a new severe recession;

  • active treatment for periodontitis;
  • having a medical condition requiring antibiotic pre-medication prior to dental procedures,
  • fixed facial or lingual orthodontic appliances or removable partial dentures;
  • antibiotic or chlorhexidine use or anti-inflammatory medications within two weeks prior to Screening visit;
  • self-report nursing, pregnancy, or intent to become pregnant during the study;
  • dental prophylaxis within two month prior to the Screening visit;
  • any diseases or conditions that could be expected to interfere with the subject safely completing the study;

Eligible subjects will be stratified based on Screening mean PPD (above or below 2mm), mean GBI (above or below 0.44), mean age (above or below 45 years old), gender (male or female) and tobacco use (yes or no). Within strata, subjects will be randomly assigned to one of the treatment groups using an encoded program. This assignment process and the distribution of test products will be conducted in a protected area that will ensure blinding of the examiner to the identity of the test products.